Lilly is investing almost $1 billion in a biologics manufacturing facility in Limerick, Ireland, and a further $2.5 million on a plant to make injectable products and devices in Alzey, Germany, including diabetes and obesity products
1a) and superior to the peptide antagonist exendin (9-39) 30
The expression of GLP-1s in genetically modified plants has been found to present a promising cost-effective approach for treating type 2 diabetes mellitus
Comparing Costs: Insurance-Covered vs
For weight loss, the main options are Wegovy (semaglutide), Saxenda (liraglutide), and Mounjaro (tirzepatide)
If youre considering weight loss injections, its important to choose clinically approved and regulated options